CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...